Scott Detmer, Ph.D.
Senior Scientist and Director, Cancer Biology
Dr. Detmer joined MitoSciences in July of 2010. Prior to that, he worked to develop anti-cancer drugs against signaling and metabolic targets in the Molecular and Cellular Pharmacology department at Exelixis. Dr. Detmer has extensive experience in cell-based assay development and mechanism of action studies. He earned his Ph.D. at the California Institute of Technology with David Chan for investigations into the molecular control of mitochondrial morphology and the role of mitochondrial dynamics in human neuropathies. He earned his B.S. in molecular biology from the University of California, San Diego.

Petr Hájek, Ph.D.
Senior Scientist and Director, Signaling Pathways
Dr. Hájek was educated at the Institute of Chemical Technology in Prague, Czech Republic, where he received a M.S. in biochemistry, and at the University of Alabama at Birmingham, where he received a Ph.D. in 1997 for studies on the biogenesis of ATP synthase. He continued his investigations on mitochondrial biology as a post-doctoral fellow and later, as a faculty member, at the California Institute of Technology with Prof. Giuseppe Attardi. He has authored 10 papers on a range of mitochondrial-related topics, including apoptosis, aging, bioenergetics and mitochondrial fusion and protein import.

Elisa Oquendo, M.D., Ph.D.
Senior Scientist and Director, Metabolic Pathways
Dr. Oquendo was educated at the University of Oxford, UK where she received her D.Phil. in 2005, and was made the Merton Americas Scholar for her research into Cytochrome c Oxidase Deficiency in humans. After completing this work, she worked as a post-doctoral researcher at the University of Pennsylvania's School of Medicine where she studied prognostic DNA biomarkers in cancer. Prior to her career in research, Dr. Oquendo worked as a Medical Doctor in under-resourced rural communities in Colombia. She received her MD in 1997 from the Universidad Pontificia Bolivariana, Medellín Colombia.

Jing Xie, M.D., Ph.D.
Senior Scientist and Director, Antibody Development
Dr. Xie was educated at the Charite Medical School of Humboldt University, Berlin, Germany, where she received her M.D. and Ph.D. in 2003 for studies on mitochondrial proteomics. She continued these studies using 2DE and MALDI-TOF in the following year of postdoctoral research at the Institute of Human Genetics of Charite, Humboldt University. Since 2005 she has served as a post-doctoral research associate in the Institute of Molecular Biology at the University of Oregon. She has studied oxidative stress and the influence of environmental toxicity to mitochondrial Complex I proteins in Parkinson's Disease patients.